ClinicalTrials.gg
Not yet recruitingNCT07863167Updated Nov 9, 2026

An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.

A Phase 2 interventional study of adebrelimab + SHR-A2009 and paclitaxel or pemetrexed combined with carboplatin +adebrelimab in Non-small Cell Lung Cancer, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Updated Nov 9, 2026Study contact changedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
660
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing adebrelimab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 16 under way, 3 of them phase 3. adebrelimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
2nd of 16
660 · median 85
Started
2026
with 7 others
Phase 2
12 of 16
12 open now
Primary completion
2028-12
later than 10 of 15 live
Registered
13th of 16
by date
Lead sponsor
3 of 16
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Among the 16 studies testing adebrelimab in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by planned enrollment, is one of 8 that started in 2026, is one of 12 in phase 2, reaches primary completion later than 10 of the 15 other live ones, and was the 13th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 16 studies testing adebrelimab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

About adebrelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing adebrelimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined with other anti-tumor therapies for perioperative treatment of resectable non-small cell lung cancer in adults.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. voluntarily participate in this clinical study, understand the research procedure and be able to sign the in writing ;
  2. At the time of signing the informed consent form, the age is 18-70 years old ( including both ends ), both men and women can.
  3. The score was 0 or 1.
  4. confirmed NSCLC, assessed as resectable or previously resected (R0).
  5. Adequate bone marrow and organ function.

Exclusion criteria

Exclusion Criteria:

  1. Participants who received systemic immunostimulatory therapy within 4 weeks prior to the first dose.
  2. Participants who received systemic therapy within 2 weeks before the first dose.
  3. Participants with active, known or suspected diseases.
  4. Other malignant tumors within 5 years before screening.
  5. Participants with a history of interstitial pneumonia or cannot exclude interstitial pneumonia; or there are other moderate to severe lung diseases that may affect respiratory function. Or received previous pneumonectomy surgery.
  6. Participants with severe cardiovascular and cerebrovascular diseases.
  7. There were bleeding symptoms or obvious bleeding tendency within 1 month before the first administration.
  8. Arterial and venous thrombosis events occurred within 3 months before the first administration.
  9. test positive.
  10. Participants with active or C.

1.Evidence of active tuberculosis infection within 1 year before the first administration.

12.Severe infection occurred within 4 weeks before the first administration. 13.History of severe allergic reactions to other monoclonal antibody / fusion protein drugs.

14. Allergy to any component of the treatment regimen. 15.Participants were known to have a history of psychotropic drug abuse, alcohol abuse or drug abuse.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
660 participants (estimated)

Study arms

  • Experimental
    group A1-1adebrelimab + SHR-A2009

    Drug: adebrelimab + SHR-A2009

  • Active comparator
    group A1-2 paclitaxel or pemetrexed combined with carboplatin +adebrelimab

    Drug: paclitaxel or pemetrexed combined with carboplatin +adebrelimab

  • Experimental
    group1 A2-1adebrelimab + SHR-A2009 (longer-interval regimen arm)

    Drug: adebrelimab + SHR-A2009

  • Experimental
    group2 A2-2adebrelimab + SHR-A2009 (shorter-interval regimen arm)

    Drug: adebrelimab + SHR-A2009

  • Active comparator
    group A2-3 adebrelimab

    Drug: adebrelimab

  • Experimental
    group1 A3-1 adebeliizumab + SHR-A2009 (longer-interval regimen arm)

    Drug: adebeliizumab + SHR-A2009

  • Experimental
    group2 A3-2 adebeliizumab + SHR-A2009 (shorter-interval regimen arm)

    Drug: adebeliizumab + SHR-A2009

  • Active comparator
    group A3-3 adebeliizumab + platinum-containing double chemotherapy

    Drug: adebeliizumab + platinum-containing double chemotherapy

  • Experimental
    group B1-1 almonertinib combined with SHR-A2009 (longer-interval regimen arm)

    Drug: almonertinib combined with SHR-A2009

  • Experimental
    group B1-2 almonertinib combined with SHR-A2009 (shorter-interval regimen arm)

    Drug: almonertinib combined with SHR-A2009

  • Active comparator
    group B1-3 almonertinib

    Drug: almonertinib

  • Experimental
    group B2-1 SHR-A2009 combined with almonertinib

    Drug: SHR-A2009 combined with almonertinib

  • Active comparator
    group B2-2 almonertinib monotherapy

    Drug: almonertinib monotherapy

Interventions

  • Drugadebrelimab + SHR-A2009

    Drug pages: Adebrelimab · Ruzaltatug rezetecan

    adebrelimab + SHR-A2009

  • Drugpaclitaxel or pemetrexed combined with carboplatin +adebrelimab

    paclitaxel or pemetrexed combined with carboplatin +adebrelimab

  • Drugadebrelimab + SHR-A2009

    Drug pages: Adebrelimab · Ruzaltatug rezetecan

    adebrelimab + SHR-A2009 (longer-interval regimen arm)

  • Drugadebrelimab + SHR-A2009

    Drug pages: Adebrelimab · Ruzaltatug rezetecan

    adebrelimab + SHR-A2009 (shorter-interval regimen arm)

  • adebrelimab

  • Drugadebeliizumab + SHR-A2009

    adebeliizumab + SHR-A2009 (longer-interval regimen arm)

  • Drugadebeliizumab + SHR-A2009

    adebeliizumab + SHR-A2009 (shorter-interval regimen arm)

  • Drugadebeliizumab + platinum-containing double chemotherapy

    adebeliizumab + platinum-containing double chemotherapy

  • Drugalmonertinib combined with SHR-A2009

    Drug pages: Aumolertinib · Ruzaltatug rezetecan

    almonertinib combined with SHR-A2009 (longer-interval regimen arm)

  • Drugalmonertinib combined with SHR-A2009

    Drug pages: Aumolertinib · Ruzaltatug rezetecan

    almonertinib combined with SHR-A2009 (shorter-interval regimen arm)

  • almonertinib

  • DrugSHR-A2009 combined with almonertinib

    Drug pages: Ruzaltatug rezetecan · Aumolertinib

    SHR-A2009 combined with almonertinib

  • almonertinib monotherapy

06

What researchers measure

Primary outcomes

  1. Part A1 : pCR rate;

    Time frame: about 24 months

  2. Part A2 : 2-year DFS rate;

    Time frame: about 24 months

  3. Part A3 : pCR rate and 18-month EFS rate;

    Time frame: about 18 months

  4. Part B1 : 2-year DFS rate.

    Time frame: about 24 months

  5. Part B2 : MPR rate.

    Time frame: about 24 months

Secondary outcomes

  1. The incidence and grade of adverse events;

    Time frame: about 48 months

  2. surgical complications;

    Time frame: about 24 months

  3. EFS

    Time frame: about 24 months ;

  4. ORR;

    Time frame: about 24 months

  5. DFS and DFS rates;

    Time frame: about 24 months

  6. OS ;

    Time frame: about 48 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2028, 26 months later.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 26 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 7, 2026
StartEst.
Oct 30, 2026
Primary completionEst.
Dec 30, 2028
CompletionEst.
Dec 30, 2030
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact's phone or email changed: •••6365→•••2973. See the current contact
Nov 9, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 2 updates
  1. Nov 9, 2026
    Contact Study contact's phone or email changed: •••6365→•••2973. See the current contact
  2. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07863167
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Oct 30, 2026 (estimated)
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Nov 9, 2026

Study contacts

Yijing Chen
Contact
yijing.chen.yc510@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adebrelimab · Ruzaltatug rezetecan · Aumolertinib

Start the discussion